Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intarcia

- PMLiVE

Merck’s Keytruda significantly extends life in some prostate cancer patients

Pivotal study identifies group of 'super responders'

- PMLiVE

Merck acquires pre-clinical biotech Calporta for up to $576m

Expands into early-stage neurodegeneration research field

- PMLiVE

FDA advisors say no to empagliflozin in type 1 diabetes

Approval of Boehringer, Lilly-partnered drug expansion looks unlikely

- PMLiVE

World Diabetes Day 2019

Many lack knowledge around type 2 diabetes risk factors, says new survey

- PMLiVE

Merck claims first-ever okay for Ebola vaccine, in Europe

Comes shortly after J&J filed its Ebola candidate with EMA

- PMLiVE

J&J catches up to Merck, files Ebola vaccine in Europe

Company is also in discussion with the FDA in the US to support regulatory filings

- PMLiVE

Sanofi reveals positive phase 3 results for long-acting insulin Toujeo

Hopes new product can offset continuing decline in franchise

- PMLiVE

Merck CFO: we’re not only about Keytruda

Highlighted the continued growth of other key cancer drugs

- PMLiVE

AZ’s Imfinzi combo scores in front-line lung cancer

Attempts to catch up to BMS and Merck in non-small cell lung cancer

- PMLiVE

Merck KGaA launches €13m seed fund for Chinese startups

Company also officially opens innovation hub in Shanghai

- PMLiVE

Merck wins CHMP recommendation for Ebola vaccine

Has also been granted priority review by FDA

- PMLiVE

GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

New data in ovarian cancer creates potential for market battle

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links